These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29421995)

  • 21. [Update: Preclinical developments for the treatment of pulmonary arterial hypertension].
    Janssen W; Ghofrani HA; Weissmann N; Grimminger F; Schermuly RT
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S157-9. PubMed ID: 19718604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
    Hansmann G; Apitz C
    Heart; 2016 May; 102 Suppl 2():ii67-85. PubMed ID: 27053700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　- Protocol of a Multicenter Randomized Control Trial.
    Akagi S; Dohi Y; Ishikawa K; Kubota K; Horimoto K; Yagi S; Hirata T; Yamamoto E; Ito H; Nakamura K
    Circ Rep; 2021 Jan; 3(2):105-109. PubMed ID: 33693297
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel Strategies in the Treatment of Pulmonary Arterial Hypertension.
    Madonna R; Cocco N
    Curr Drug Targets; 2016; 17(7):817-23. PubMed ID: 26201488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New paradigm for pulmonary arterial hypertension treatment.
    Tamura Y; Channick RN
    Curr Opin Pulm Med; 2016 Sep; 22(5):429-33. PubMed ID: 27434819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the discovery of drugs that treat pulmonary arterial hypertension.
    Zolty R
    Expert Opin Drug Discov; 2023 Apr; 18(4):445-466. PubMed ID: 37013267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macitentan for the treatment of pulmonary arterial hypertension.
    Hong IS; Coe HV; Catanzaro LM
    Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selexipag for the treatment of pulmonary arterial hypertension.
    Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
    Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging drugs for pulmonary hypertension.
    Girgis RE
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):71-85. PubMed ID: 20095920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
    Thakkar V; Nikpour M; Stevens WM; Proudman SM
    Intern Med J; 2015 Mar; 45(3):248-54. PubMed ID: 25735576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.
    de Raaf MA; Beekhuijzen M; Guignabert C; Vonk Noordegraaf A; Bogaard HJ
    Reprod Toxicol; 2015 Aug; 56():45-51. PubMed ID: 26111581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
    Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel investigational therapies for treating pulmonary arterial hypertension.
    Sardana M; Moll M; Farber HW
    Expert Opin Investig Drugs; 2015; 24(12):1571-96. PubMed ID: 26484967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Riociguat for the treatment of pulmonary hypertension.
    Meis T; Behr J
    Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current and advancing treatments for pulmonary arterial hypertension in childhood.
    Zijlstra WM; Ploegstra MJ; Berger RM
    Expert Rev Respir Med; 2014 Oct; 8(5):615-28. PubMed ID: 25047735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.